Sign in
CompletedPhase 4

Optimization of Minocycline for Helicobacter Pylori Rescue Treatment

Key facts

Who runs it
Shanghai Jiao Tong University School of Medicine
Where
China4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
480 people enrolled
Started
21 Aug 2024
Ended
21 Feb 2026
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Vonoprazan
  • Bismuth Potassium Citrate
  • Tetracycline,Metronidazole
  • Minocycline,Metronidazole
Record updated
25 March 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Ability and willingness to participate in the study and to sign and give informed consent
  • Confirmed H. pylori infection and with previous treatment experience

Who cannot take part

  • Previous history of tuberculosis
  • administration of antibiotics, bismuth, antisecretory drugs, or Chinese herb medicine in the preceding 8 weeks
  • history of gastrectomy
  • Allergy to any of the study drugs
  • severe systemic diseases or malignancy
  • under 18 or over 80 years old
  • subjects naive to H. pylori treatment,
  • pregnant or lactating women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The efficacy of bismuth-containing quadruple therapy with minocycline and metronidazole was not inferior to classical bismuth quadruple therapy for refractory H. pylori infection, though also accompanied with high occurrence of adverse events (55.4%). Optimization of minocycline-based regimen to achieve high eradication rate with fewer adverse events is imperative. This study aimed to compare the efficacy and tolerability of a 14-day bismuth-containing quadruple rescue therapy with different dosage of minocycline and metronidazole compared to classical bismuth quadruple therapy.

The 4 groups in the trial

  • Minocycline group ATreatment being tested

    Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Minocycline 50mg tid, Metronidazole 400mg tid

    Treatment: Vonoprazan, Bismuth Potassium Citrate, and Minocycline,Metronidazole

  • Minocycline group BTreatment being tested

    Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Minocycline 50mg bid, Metronidazole 400mg qid

    Treatment: Vonoprazan, Bismuth Potassium Citrate, and Minocycline,Metronidazole

  • Minocycline group CTreatment being tested

    Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Minocycline 50mg bid, Metronidazole 400mg tid

    Treatment: Vonoprazan, Bismuth Potassium Citrate, and Minocycline,Metronidazole

  • Tetracycline groupExisting treatment, for comparison

    Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Tetracycline 500mg qid, Metronidazole 400mg qid

    Treatment: Vonoprazan, Bismuth Potassium Citrate, and Tetracycline,Metronidazole

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimization of Minocycline-containing Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: a Multicentre, Randomized Controlled Trial
Publications
Record updated
25 March 2026